![]() |
Volumn 91, Issue 1, 2012, Pages 89-92
|
Salvage therapy with lenalidomide and dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, and thalidomide.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTINEOPLASTIC AGENT;
BORONIC ACID DERIVATIVE;
BORTEZOMIB;
DEXAMETHASONE;
DRUG DERIVATIVE;
IMMUNOSUPPRESSIVE AGENT;
LENALIDOMIDE;
MELPHALAN;
PYRAZINE DERIVATIVE;
THALIDOMIDE;
ADULT;
AGED;
AMYLOIDOSIS;
ARTICLE;
DRUG RESISTANCE;
HUMAN;
MALE;
METHODOLOGY;
MIDDLE AGED;
PATHOPHYSIOLOGY;
RECURRENT DISEASE;
SALVAGE THERAPY;
SURVIVAL RATE;
TREATMENT OUTCOME;
ADULT;
AGED;
AMYLOIDOSIS;
ANTINEOPLASTIC AGENTS;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
BORONIC ACIDS;
DEXAMETHASONE;
DRUG RESISTANCE, NEOPLASM;
HUMANS;
IMMUNOSUPPRESSIVE AGENTS;
MALE;
MELPHALAN;
MIDDLE AGED;
PYRAZINES;
RECURRENCE;
SALVAGE THERAPY;
SURVIVAL RATE;
THALIDOMIDE;
TREATMENT OUTCOME;
|
EID: 84857087905
PISSN: None
EISSN: 14320584
Source Type: Journal
DOI: 10.1007/s00277-011-1244-x Document Type: Article |
Times cited : (82)
|
References (0)
|